Trial Profile
A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 03 May 2014 New trial record